FDA Determines Regulatory Review Period for PADCEV Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for PADCEV, a human biological product, following a submission to the US Patent and Trademark Office (USPTO) for patent extension, as required by law.